logo
AI can be more persuasive than humans in debates, scientists find

AI can be more persuasive than humans in debates, scientists find

Yahoo19-05-2025
Artificial intelligence can do just as well as humans, if not better, when it comes to persuading others in a debate, and not just because it cannot shout, a study has found.
Experts say the results are concerning, not least as it has potential implications for election integrity.
'If persuasive AI can be deployed at scale, you can imagine armies of bots microtargeting undecided voters, subtly nudging them with tailored political narratives that feel authentic,' said Francesco Salvi, the first author of the research from the Swiss Federal Institute of Technology in Lausanne. He added that such influence was hard to trace, even harder to regulate and nearly impossible to debunk in real time.
'I would be surprised if malicious actors hadn't already started to use these tools to their advantage to spread misinformation and unfair propaganda,' Salvi said.
But he noted there were also potential benefits from persuasive AI, from reducing conspiracy beliefs and political polarisation to helping people adopt healthier lifestyles.
Writing in the journal Nature Human Behaviour, Salvi and colleagues reported how they carried out online experiments in which they matched 300 participants with 300 human opponents, while a further 300 participants were matched with Chat GPT-4 – a type of AI known as a large language model (LLM).
Each pair was assigned a proposition to debate. These ranged in controversy from 'should students have to wear school uniforms'?' to 'should abortion be legal?' Each participant was randomly assigned a position to argue.
Both before and after the debate participants rated how much they agreed with the proposition.
In half of the pairs, opponents – whether human or machine – were given extra information about the other participant such as their age, gender, ethnicity and political affiliation.
The results from 600 debates revealed Chat GPT-4 performed similarly to human opponents when it came to persuading others of their argument – at least when personal information was not provided.
Related: The AI Con by Emily M Bender and Alex Hanna review – debunking myths of the AI revolution
However, access to such information made AI – but not humans – more persuasive: where the two types of opponent were not equally persuasive, AI shifted participants' views to a greater degree than a human opponent 64% of the time.
Digging deeper, the team found persuasiveness of AI was only clear in the case of topics that did not elicit strong views.
The researchers added that the human participants correctly guessed their opponent's identity in about three out of four cases when paired with AI. They also found that AI used a more analytical and structured style than human participants, while not everyone would be arguing the viewpoint they agree with. But the team cautioned that these factors did not explain the persuasiveness of AI.
Instead, the effect seemed to come from AI's ability to adapt its arguments to individuals.
'It's like debating someone who doesn't just make good points: they make your kind of good points by knowing exactly how to push your buttons,' said Salvi, noting the strength of the effect could be even greater if more detailed personal information was available – such as that inferred from someone's social media activity.
Prof Sander van der Linden, a social psychologist at the University of Cambridge, who was not involved in the work, said the research reopened 'the discussion of potential mass manipulation of public opinion using personalised LLM conversations'.
He noted some research – including his own – had suggested the persuasiveness of LLMs was down to their use of analytical reasoning and evidence, while one study did not find personal information increased Chat-GPT's persuasiveness.
Prof Michael Wooldridge, an AI researcher at the University of Oxford, said while there could be positive applications of such systems – for example, as a health chatbot – there were many more disturbing ones, includingradicalisation of teenagers by terrorist groups, with such applications already possible.
'As AI develops we're going to see an ever larger range of possible abuses of the technology,' he added. 'Lawmakers and regulators need to be pro-active to ensure they stay ahead of these abuses, and aren't playing an endless game of catch-up.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

I missed Nvidia – could this be the next big US growth stock?
I missed Nvidia – could this be the next big US growth stock?

Yahoo

timean hour ago

  • Yahoo

I missed Nvidia – could this be the next big US growth stock?

Let's be honest — most of us missed the boat on Nvidia (NASDAQ: NVDA). And by the time we realised just how vital graphics processing units (GPUs) would become to artificial intelligence (AI), the share price had already soared into the stratosphere. Over the past five years, the stock has climbed almost 1,600%. In the last six months alone, it's up almost 50%, adding over $1.5trn to its market value. It's now the most valuable company in the world, overtaking Microsoft and Apple in June. I have exposure to the stock through several ETFs and investment trusts, so I didn't entirely miss out on the action. But I certainly made nowhere near the gains I would have had I bought individual shares. Which makes me wonder, how did Nvidia get here, and what stock could be next? Crunching the numbers The numbers behind the hype are jaw-droppingly impressive. For the fiscal year ending January 2025, revenue reached $130bn, a staggering increase from $27bn just two years ago. Net income exploded from $4.3bn in 2022 to more than $70bn this year. And its margins are enormous — a return on equity of 115% and gross margins consistently above 70%. Yet despite the parabolic growth, I don't think it's entirely overvalued yet. In fact, I still think it's worth considering as a long-term investment. It's a world-class company with room to expand further and the global AI arms race is just getting started – with Nvidia at its core. Realistically, though, the biggest gains have already been made. Buying now means betting on continued dominance that may already be priced in, which is a risk. The stock trades at a price-to-earnings (P/E) ratio of 45 – not outrageous considering its growth, but not cheap either. So where should investors look if they want to catch the next killer growth stock before it becomes a trillion-dollar giant? Could SymphonyAI be next? One company on my radar is SymphonyAI, a private US firm reportedly preparing for a Nasdaq IPO later this year. It's not yet listed, but when it does go public, I'll be watching closely. Founded by billionaire Romesh Wadhwani, it specialises in applying AI to specific industry verticals – retail, finance, manufacturing, and healthcare. It doesn't build chips like Nvidia, but it builds the enterprise software that helps businesses harness AI to improve decision-making and productivity. Unlike many AI startups, SymphonyAI already has real revenues and customers. Its retail division serves over 1,200 brands, while its industrial arm works with giants like Nestlé and ArcelorMittal. While financials are still private, it reportedly generates hundreds of millions in annual revenue and is growing fast. If the IPO goes ahead this autumn, it could be one of the most closely watched tech listings of the year. Long-term mindset Nvidia's success was powered by timing, technology, and a growing reliance on data. It may still reward shareholders but the days of 10x returns are likely behind us. SymphonyAI might never reach Nvidia's heights but it could offer early-stage exposure to enterprise AI – the next leg of this growth story. If the valuation is right, it could turn out to be a once-in-a-decade opportunity. The post I missed Nvidia – could this be the next big US growth stock? appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Mark Hartley has no position in any of the shares mentioned. The Motley Fool UK has recommended Apple, Microsoft, and Nvidia. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

OpenAI Raises $8.3 Billion at $300 Billion Valuation
OpenAI Raises $8.3 Billion at $300 Billion Valuation

Business Insider

time2 hours ago

  • Business Insider

OpenAI Raises $8.3 Billion at $300 Billion Valuation

Microsoft-backed (MSFT) AI firm OpenAI has raised $8.3 billion in fresh funding at a $300 billion valuation, according to The New York Times. Indeed, the raise is part of the company's bigger $40 billion fundraising goal for 2025 and came months earlier than expected. It is worth noting that OpenAI had already secured $2.5 billion in March and initially planned to add another $7.5 billion later this year, but accelerated its timeline as investor demand surged due to the company's fast growth. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Indeed, The Information reported on Thursday that OpenAI reached $12 billion in annualized revenue and surpassed 700 million weekly active ChatGPT users. Meanwhile, the Times suggested that the number may be closer to $13 billion and could hit $20 billion by the end of the year. It also helps that the Trump administration's AI Action Plan and ongoing talks with Microsoft could push OpenAI toward its goal of becoming a fully for-profit company. As a result, the latest round was led by Dragoneer Investment Group, which invested $2.8 billion in one of its most significant bets to date. Other new backers included Blackstone (BX), TPG (TPG), and T. Rowe Price (TROW), alongside well-known firms like Andreessen Horowitz, Founders Fund, Sequoia Capital, and Fidelity. Interestingly, though, some early investors were reportedly frustrated because they received smaller allocations in this round, as OpenAI prioritized bringing in strategic partners to support its next growth phase. Is MSFT Stock a Buy? Turning to Wall Street, analysts have a Strong Buy consensus rating on MSFT stock based on 33 Buys and two Holds assigned in the last three months. Furthermore, the average MSFT price target of $614.72 per share implies 17.3% upside potential.

Tempus AI Stock Before Q2 Earnings Release: To Buy or Not to Buy?
Tempus AI Stock Before Q2 Earnings Release: To Buy or Not to Buy?

Yahoo

time2 hours ago

  • Yahoo

Tempus AI Stock Before Q2 Earnings Release: To Buy or Not to Buy?

Tempus AI, Inc. TEM is scheduled to report second-quarter 2025 results on Aug. 8. In the last reported quarter, the company's adjusted loss of 24 cents was narrower than the Zacks Consensus Estimate of a loss of 27 cents per share. Tempus AI, which went public in June 2024, exceeded estimates in two of the trailing four quarters and missed in two, the average negative earnings surprise being 2.07%. The Zacks Consensus Estimate for revenues is currently pegged at $299.3 million for the second quarter, implying an 80.4% improvement over the year-ago period. The Zacks Consensus Estimate for the second-quarter bottom line has narrowed by 4 cents to a loss of 23 cents per share over the past 90 days. TEM's Earnings Estimate Revision Trend Image Source: Zacks Investment Research Throughout the second quarter of 2025, Tempus AI had an impressive run on the bourses with a 34.5% gain. Despite macroeconomic challenges, including escalating trade tensions that broadly impacted the healthcare technology sector, the company witnessed strong momentum, primarily driven by a series of strategic acquisitions and partnerships in the field of AI-driven precision medicine. During this period, the company not only surpassed the 9.3% gain posted by the broader industry but also significantly outperformed the 3.4% decline of the Medical sector. The S&P 500 benchmark index gained 10.7% during this period. The company has also outperformed other players in the health infotech field, like 10x Genomics TXG and SOPHiA GENETICS SOPH. While TXG gained 33.5%, SOPH declined 2.3% during the said period. Q2 Price Comparison Image Source: Zacks Investment Research Let's see how things have shaped up for TEM shares prior to this announcement: Key Factors to Note Prior to Tempus AI's Q2 Earnings Tempus AI recently announced a three-year, $200 million foundational model partnership with AstraZeneca AZN and Pathos, which is expected to have contributed to its second-quarter performance. This non-exclusive data licensing agreement aims to develop the world's largest foundation model in oncology using over 300 petabytes of Tempus' multimodal data. With the first version of the model expected in 9-12 months, the deal is already transforming Tempus AI's data monetization trajectory. Management confirmed that revenues from this deal will be recognized ratably over the three-year term, starting in the second quarter. Tempus AI's hereditary testing segment, which contributed meaningfully to first-quarter growth, is expected to have maintained the trend this time too. When Tempus acquired Ambry Genetics, it guided mid-to-high teens growth, but the segment exceeded expectations with a 23% unit increase. While management has been cautious about projecting ongoing acceleration, they have also expressed confidence in the long-term potential for broader hereditary screening applications, ranging from cancer to cardiovascular and neurological risk. Tempus continued to expand its diagnostics portfolio with the recent FDA clearance of ECG-Low EF, its second AI-powered ECG tool for detecting low ejection fraction, further strengthening its position in cardiology and extending its reach beyond oncology. Meanwhile, the company launched xM for TRM, a liquid biopsy assay for monitoring immunotherapy response, which showed promising early data at ASCO 2025. These likely contributed to the second-quarter top line too. Tempus AI is advancing its digital health strategy by integrating Tempus One, its GenAI clinical assistant, into EHR systems, enabling physicians to query data, access guidelines and streamline workflows. The launch of Agent Builder for custom GenAI tools further deepens its role in clinical settings. Tempus One too is expected to have witnessed strong customer adoption during the second quarter. However, despite strong top-line growth and product momentum, Tempus AI in 2025 is facing a few near-term challenges. The company remains unprofitable, with an adjusted EBITDA loss of $16.2 million in the first quarter. Though the loss narrowed year over year, it raised questions about the timeline to profitability amid ongoing R&D investments. Additionally, while the AstraZeneca-Pathos foundation model deal is significant, its revenues will be recognized ratably over three years, limiting short-term financial impact. Further, investments tied to these updates, including product development, regulatory efforts, and marketing, are likely to have pushed operating expenses higher in the second quarter, putting some pressure on short-term profitability. Broader macroeconomic factors, like tariffs, hospital budget constraints and biotech funding trends, could also affect adoption rates. Expensive Valuation TEM's stock is currently overvalued compared to its industry, as shown in the chart below. TEM is currently trading at a forward 12-month price-to-sales (P/S) ratio of 6.86, a premium to the broader industry's average of 5.80X. It also trades higher than other industry players like 10x Genomics (2.70X) and SOPHiA GENETICS (2.40X). However, the stock is trading below its one-year median of 8.00X, suggesting that it has moderated somewhat from its historical highs. Image Source: Zacks Investment Research Our Take With the AI market projected to grow exponentially in the coming years, Tempus AI is well-positioned to capitalize on expanding opportunities. With a strong financial outlook and efforts to improve healthcare outcomes, TEM presents a unique opportunity for investors seeking high returns from the AI and healthcare sectors. Yet, despite the company's several recent upsides, its premium valuation and lack of near-term profitability are limiting this Zacks Rank #3 (Hold) stock's near-term gains. While current shareholders should hold their positions, new investors should wait for the stock to retract some of its recent gains, providing a better entry point. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report 10x Genomics (TXG) : Free Stock Analysis Report SOPHiA GENETICS SA (SOPH) : Free Stock Analysis Report Tempus AI, Inc. (TEM) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store